C Michael Gibson Discussing The Results of The Phase III OCEANIC-STROKE Trial with Mike Sharma
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%.
The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year.
There was no increase in mild or severe bleeding or intracranial bleeding
63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy
Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin
All benefit with no increase in bleeding risk
View slides here.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers